Skip to content

A study to see the relation between the clinical problems oand the diagnostic tests of a patient with suspicion of Tuberculosis abdomen along with the management of such a patient

Clinico-investigational correlation and management of abdominal tuberculosis in pediatric population: A prospective observational study.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/06/026205
Enrollment
50
Registered
2020-06-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A183- Tuberculosis of intestines, peritoneum and mesenteric glands

Interventions

Intervention1: Nil: Nil

Sponsors

AIIMS Rishikesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Definite abdominal tuberculosis patients with consent given for study and follow up. 2. Probable abdominal tuberculosis patients with consent given for study and follow up.

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed as MDR (Multi drug resistant) TB. 2. Patients put on MDR TB treatment on clinical basis.

Design outcomes

Primary

MeasureTime frame
1. Relapse: participants who had new symptoms and signs of TB after resolution of disease and completion of antituberculous treatment (ATT). 2. Clinical cure: Participants who completed treatment according to the original treatment plan without evidence of treatment failure at the end of treatment. Timepoint: 2 years

Secondary

MeasureTime frame
1. Death from any cause during the treatment. 2. Treatment failure 3. Default 4. Poor adherence 5. Complete healing of active lesions, documented by endoscopy or histopathology.Timepoint: 2 years

Countries

India

Contacts

Public ContactEnono Yhoshu

All India Institute of Medical Sciences, Rishikesh, India

enoyo83@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026